单克隆抗体药物的群体药理学进展
Shouhua Mu1,2, Xiaojing Zhang1, Jingyan Jin1,2
1Pharmacy of the 940th Hospital of Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, China; and.
Therapeutic drug monitoring
|August 27, 2025
概括
在单克隆抗体 (mAb) 药物治疗中,群体药物动力学 (PPK) 模型至关重要. 本综述强调了目前对mAb药物的PPK研究,为改善疗效和安全提供了临床实践和治疗药物监测的信息.
科学领域:
- 药理学
- 免疫学
- 药物开发
背景情况:
- 单克隆抗体 (mAbs) 在治疗瘤和自身免疫性疾病方面至关重要.
- 在mAb的药理动力学显著的个体间变异影响药物的有效性和安全性.
- 个性化药物输送和治疗药物监测对于优化mAb治疗至关重要.
研究的目的:
- 对单克隆抗体 (mAb) 药物的当前人群药理学 (PPK) 研究进行审查.
- 为 mAb 药物治疗的临床个性化提供参考.
主要方法:
- 在PubMed和中国知识网络的文献搜索 (2017-2024年).
- 根据标题和摘要选择并详细审查30篇相关文章.
- 最终分析包括15篇文章,并从参考清单中获取其他相关研究.
主要成果:
- 六项研究利用已有的PPK模型来优化剂量方案.
- 六项研究专注于建立PPK模型,需要进行进一步的药理学研究以优化治疗方案.
- 目前有两项研究处于mAb药物开发临床试验阶段.
结论:
- 本综述综合了mAb药物PPK研究的当前进展.
- 这些发现支持通过PPK建模进行mAb药物治疗的临床个性化.
- 强调PPK模型对于治疗药物监测和个性化医疗的重要性.
相关概念视频
Analysis of Population Pharmacokinetic Data
382
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
382
Drug Distribution: Plasma Protein Binding
6.6K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
6.6K
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
273
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
273
Physiological Pharmacokinetic Models: Assumption with Protein Binding
91
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
91
Nonlinear Pharmacokinetics: Overview
544
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
544
Hybridoma Technology
15.3K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.3K


